Spots Global Cancer Trial Database for itacitinib
Every month we try and update this database with for itacitinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer | NCT03425006 | Non Small Cell ... | Itacitinib Pembrolizumab | 18 Years - | University of Pennsylvania | |
| An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | NCT02917993 | Lung Cancer | Itacitinib Osimertinib | 18 Years - | Incyte Corporation | |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) | NCT04629508 | Myelofibrosis Polycythemia Ve... Thrombocythemia | itacitinib | 18 Years - | Incyte Corporation | |
| INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma | NCT02456675 | Refractory Hodg... Recurrent Adult... | INCB040093 Mono... INCB040093 itacitinib | 18 Years - | Incyte Corporation | |
| Itacitinib + Everolimus in Hodgkin Lymphoma | NCT03697408 | Classical Hodgk... | Itacitinib Everolimus | 18 Years - | University of Pennsylvania | |
| An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation | |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | NCT03989466 | Recurrent T-Cel... T-Cell Prolymph... | Alemtuzumab Itacitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | NCT02646748 | Colorectal Canc... Endometrial Can... Melanoma Head and Neck C... Lung Cancer MMR-deficient T... Breast Cancer Pancreatic Canc... Renal Cell Carc... Solid Tumors UC (Urothelial ... | Pembrolizumab itacitinib INCB050465 | 18 Years - | Incyte Corporation | |
| INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma | NCT02456675 | Refractory Hodg... Recurrent Adult... | INCB040093 Mono... INCB040093 itacitinib | 18 Years - | Incyte Corporation | |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas | NCT03670069 | Metastatic Leio... Metastatic Syno... Metastatic Undi... Advanced Myxoid... Advanced Soft T... Metastatic Myxo... Metastatic Roun... Metastatic Soft... Refractory Leio... Refractory Myxo... Refractory Roun... Refractory Soft... Refractory Syno... Refractory Undi... Advanced Leiomy... Advanced Synovi... Advanced Undiff... Metastatic Chon... | Itacitinib Laboratory Biom... | 18 Years - | Fred Hutchinson Cancer Center | |
| Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors | NCT02559492 | Solid Tumors | Itacitinib Epacadostat Itacitinib INCB050465 | 18 Years - | Incyte Corporation | |
| Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors | NCT05660421 | Hematopoietic a... Malignant Solid... | Itacitinib Corticosteroid Endoscopic Proc... Skin biopsy Biospecimen Col... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | NCT05823571 | Leukemia, Acute Myelodysplastic... Myelomonocytic ... T-cell Prolymph... CML Myeloproliferat... Multiple Myelom... Plasma Cell Leu... | Itacitinib | 60 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors | NCT02559492 | Solid Tumors | Itacitinib Epacadostat Itacitinib INCB050465 | 18 Years - | Incyte Corporation | |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) | NCT02018861 | B-Cell Malignan... | Parsaclisib Itacitinib Rituximab Ifosfamide Carboplatin Etoposide | 18 Years - | Incyte Corporation | |
| Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors | NCT01858883 | Solid Tumors Pancreatic Canc... | itacitinib Gemcitabine nab-paclitaxel filgrastim | 18 Years - | Incyte Corporation | |
| Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | NCT05757219 | Diffuse Large B... | Itacitinib Chimeric antige... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | NCT02257619 | NSCLC (Non-smal... | Itacitinib docetaxel | 18 Years - | Incyte Corporation | |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | NCT04591431 | Breast Cancer Gastrointestina... Non Small Cell ... Other Cancer | Erlotinib Trastuzumab Trastuzumab emt... Pertuzumab Lapatinib Everolimus Vemurafenib Cobimetinib Alectinib Brigatinib Palbociclib Ponatinib Vismogedib Itacitinib Ipatasertib Entrectinib Atezolizumab Nivolumab Ipilimumab Pemigatinib Oncology Drugs Pralsetinib Selpercatinib Talazoparib Tepotinib Alpelisib | 18 Years - | Fondazione per la Medicina Personalizzata | |
| Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | NCT05364762 | Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myeloproliferat... Primary Myelofi... Secondary Myelo... | Cyclophosphamid... Itacitinib Peripheral Bloo... Quality-of-Life... Tacrolimus | - 80 Years | City of Hope Medical Center | |
| Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | NCT02355431 | Solid Tumors an... NSCLC (Non-smal... | Itacitinib erlotinib placebo | 18 Years - | Incyte Corporation | |
| Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | NCT05364762 | Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Myeloproliferat... Primary Myelofi... Secondary Myelo... | Cyclophosphamid... Itacitinib Peripheral Bloo... Quality-of-Life... Tacrolimus | - 80 Years | City of Hope Medical Center | |
| An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation | |
| An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer | NCT02917993 | Lung Cancer | Itacitinib Osimertinib | 18 Years - | Incyte Corporation | |
| Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation | NCT04127721 | Allogeneic Stem... Hematologic and... Hematopoietic a... | Allogeneic Hema... Busulfan Fludarabine Itacitinib Methotrexate Tacrolimus | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer | NCT03425006 | Non Small Cell ... | Itacitinib Pembrolizumab | 18 Years - | University of Pennsylvania | |
| An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis | NCT01633372 | MPN (Myeloproli... | itacitinib | 18 Years - | Incyte Corporation | |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | NCT05823571 | Leukemia, Acute Myelodysplastic... Myelomonocytic ... T-cell Prolymph... CML Myeloproliferat... Multiple Myelom... Plasma Cell Leu... | Itacitinib | 60 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | NCT03989466 | Recurrent T-Cel... T-Cell Prolymph... | Alemtuzumab Itacitinib | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT02760485 | Lymphoma | itacitinib ibrutinib | 18 Years - | Incyte Corporation |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
